In HRR-deficient cells, such as CML, PARPi treatment in combination with METTL3 inactivation may induce a "synthetic lethality" effect, where the combined inhibition of two DNA repair pathways becomes lethal to the cancer cells. Here, METTL3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.